HTL S.A.S. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

1992

Location

France

Primary Industry

Biotechnology

About

Founded in 1992 and based in Javene, France, HTL S.A.S. is a biotechnology company that produces hyaluronic acid (HA) and other biological polymer solutions for medical purposes. As of 2024, the company is headed by its CEO Francois Fournier. In November 2021, Montagu Private Equity and Partners Group agreed to acquire HTL S.A.S. from Bridgepoint, Tethys Invest, and Naxicap Partners. The company offers a wide range of biopolymers which are pharmaceutical grade. The company's offering includes pharmaceutical-grade hyaluronic acid, pharmaceutical-grade DNA, cosmetic-grade DNA, heparosan, and oligo HA.

Current Investors

Montagu Private Equity, Partners Group, Téthys

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopolymers, Biopharmaceuticals

Website

www.htlbiotech.com

Total Amount Raised

Subscriber access only

Deals

Deals Type
Add-on, Spin-Off +1 more
Buyout
Private Debt
Secondary Buyout
Buyout

Deal Status	Target (s)	Deal Date
Completed	Modern Meadow Inc.'s human recombinant collagen platform	06 May 2024
Completed	HTL S.A.S.	12 Nov 2021
Completed	HTL S.A.S.	01 Dec 2018
Completed	HTL S.A.S.	08 Oct 2018
Completed	HTL S.A.S.	01 Feb 2017

Displaying 1-5 of 6

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.